Samstag, 27. April 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
MEFOX

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

Rekrutierend

NCT-Nummer:
NCT05212012

Studienbeginn:
Februar 2022

Letztes Update:
15.06.2023

Wirkstoff:
Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml)

Indikation (Clinical Trials):
Colorectal Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
AIO-Studien-gGmbH

Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany)

Studienleiter

Thomas Seufferlein, Prof.Dr.med.
Principal Investigator
Ulm University Hospital, Department of Internal Medicine I

Kontakt

Studienlocations
(2 von 2)

Studien-Informationen

Brief Summary:

This is a phase I/II-trial with D,L-methadone and mFOLFOX6 in the treatment of patients with

histologically confirmed chemo-refractory colorectal carcinoma.

The aim of the phase-I trial is to evaluate the toxicity-profile and the dose-limiting

toxicity of D,L-methadone combined with mFOLFOX6. Furthermore, to estimate the maximum

tolerated dose and the recommended dose for phase-II-trial in the treatment of patients with

histologically confirmed colorectal carcinoma not amenable to or progressing while having

received all standard therapies.

The primary endpoint of the randomized phase-II study is to determine the disease control

rate 12 weeks after randomization of patients with histologically confirmed advanced

colorectal carcinoma upon treatment with D,L methadone plus mFOLFOX6 versus mFOLFOX6 alone.

Overall response rate according to RECIST1.1, progression free survival (PFS), overall

survival (OS), quality of life (QoL) according to the EORTC QLQc30 questionnaire,

patient-reported outcomes and safety will be evaluated as secondary objectives.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Advanced, histologically confirmed, metastatic colorectal carcinoma not suitable for

resection and chemorefractory or Previously employed chemotherapy regimens and agents

should comprise the following: Fluoropyrimidines, oxaliplatin, irinotecan,

antiangiogenic agents (bevacizumab, aflibercept or ramucirumab), anti-EFGR-mAbs (in

case of all-Ras-wildtype and left-sided primary tumor) and Trifluridin/Tipiracil

(TAS102)

- Microsatellite stable subset (MSS) of colorectal cancer

- Prior antineoplastic therapy or radiochemotherapy is allowed up to two weeks prior to

start of the study medication. However, for the phase II part of the trial, failure of

this strategy must be confirmed. In case of prior radiotherapy/radiochemotherapy the

target lesion used for tumor evaluation must not be in the radiation field.

- There must be an oxaliplatin free period of at least 6 months prior to start of the

study medication.

- No polyneuropathy of > grade 1

- Tumor-related ECOG performance status 0-2

- Anticipated life expectancy ≥ 12 weeks

- Creatinine clearance ≥ 30 ml/min

- Serum total bilirubin level ≤ 3 x ULN.

- ALT and AST ≤ 2.5 x ULN or ≤ 5.0 x ULN in the presence of liver metastasis

(established after adequate biliary drainage)

- White blood cell count ≥ 3.5 x 106/ml, neutrophil granulocytes count ≥ 1,5 x 106/ml,

platelet count ≥ 100 x 106/ml

- Pain that has to be controllable without concomitant use of opioids

- Signed informed consent according to ICH/GCP and national/local regulations

(participation in translational research is obligate)

- None of the following concomitant medications: MAO-B-Inhibitors, strong inductors or

inhibitors of CYP3A4, antiarrhythmic drugs of class I and III or other drugs that have

potential for QT-prolongation

- Age ≥ 18 years

- At least one measurable target lesion according to RECIST 1.1. Pre-irradiated or

locally treated lesions must not be used as target lesions.

Exclusion Criteria:

- Microsatellite unstable CRC (MSIhigh)

- Chronic infectious diseases, immune deficiency syndromes

- Polyneuropathy >grade I according to CTCAE V4.03

- Premalignant hematologic disorders, e.g. myelodysplastic syndrome

- Disability to understand and sign written informed consent document

- Past or current history of malignancies except for the indication under this study and

curatively treated:

- Basal and squamous cell carcinoma of the skin

- In-situ carcinoma of the cervix

- Other malignant disease without recurrence after at least 3 years of follow-up

- Clinically significant cardiovascular disease (incl. myocardial infarction, unstable

angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia)

6 months before enrollment

- History of or evidence upon physical examination of CNS disease unless adequately

treated (e.g. primary brain tumor, seizure not controlled with standard medical

therapy or history of stroke).

- Severe non-healing wounds, ulcers or bone fractions

- Evidence of bleeding diathesis or coagulopathy

- Patients not receiving therapeutic anticoagulation must have an INR ≤ 1.4 or PTT ≤ 40

sec within 28 days prior to randomization. The use of full dose anticoagulants is

allowed as long as the INR or PTT is within therapeutic limits (according to the

medical standard in the institution)

- Major surgical procedures or significant traumatic injury within 28 days prior to

randomization, or anticipation of the need for major surgical procedure during the

course of the study.

- Pregnancy or breastfeeding women.

- Use of cannabinoids because of overlapping and /or potentiating of potential side

effects

- Concomitant daily use of opioids in the last 3 months including methadone prior start

of study medication

- Subjects with known allergies to the study drugs or to any of its excipients.

- Treatment with another investigational drug or participation in another interventional

trial (within the 14 days prior randomization or 5 plasma half-lifes of the used

investigational drug, whatever is longer)

- Congenital QT-syndrome.

- Alcohol abuse.

- Bronchial asthma.

- Liver cirrhosis > Child-Pugh classification A.

- Any psychological, familial, sociological or geographical condition potentially

compromising compliance with the study protocol and the follow-up schedule; those

conditions should be discussed with the patient prior to registration in the trial

Studien-Rationale

Primary outcome:

1. Evaluation of the recommended dose for phase-II-trial (Time Frame - 18 months):
Evaluation of the toxicity-profile of D,L-methadone and the dose-limiting toxicity (DLT) in combination with mFOLFOX6

2. Disease control rate 12 weeks after randomization (ITT-population) (Time Frame - 12 weeks after randomization):
Evaluation of the disease control rate of D,L-methadone plus mFOLFOX6 compared to mFOLFOX6 alone in the treatment of patients with advanced colorectal cancer. The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1.

Secondary outcome:

1. Disease control rate (DCR) 12 weeks after randomization (per-protocol-population) (Time Frame - 12 weeks):
The disease control rate is defined as response (CR or PR) or stabilization (SD) of the tumor disease at 12 weeks after randomization (DCR) according to RECIST1.1

2. Overall response rate (Time Frame - 46 months):
All tumor evaluation is performed according to RECIST 1.1

3. patient diary (Time Frame - 46 months):
Collection compliance with a diary

4. Progression-free survival (Time Frame - after 46 months):
Progression-free survival (PFS) will be defined as the time from randomization to the time of progress (according to RECIST 1.1) or death, or to the date of last tumor assessment without any such event (censored observation)

5. Overall survival (Time Frame - 46 months):
The duration of overall survival (OS) will be determined by measuring the time interval from randomization to the date of death or last observation (censored)

6. Quality of life assessment (Time Frame - 46 months):
EORTC QLQ-C30 ("European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30)" ). The EORTC QLQ-C30 is composed of a global health status/QoL-score, five function scales, three symptom scales and five single items (dyspnea, insomnia, appetite loss, constipation, diarrhea). Each item has four response alternatives: (1) "not at all", (2) "a little", (3) "quite a bit", and (4) "very much" - except the two items of the global health-status/quality of life scale which have response options ranging from (1) "very poor" to (7) "excellent".

7. Adverse events (Time Frame - 46 months):
Evaluation of the safety- and tolerability profile

Geprüfte Regime

  • Maximum tolerated dose, MTD: D,L-methadone hydrochloride (Methasan® 10 mg/ml):
    Dose Level D,L-methadone hydrochloride (Methasan® 10 mg/ml) In dose level I a maximum of 30 mg/day (15 mg (1,5 ml) 1-0-1) In dose level II a maximum of 35 mg/ day (17.5 mg (1,75 ml) 1-0-1) In dose level III a maximum of 40 mg/day (20 mg (2,0 ml) 1-0-1)

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.